Sitedeki bütün künyeler

İlaç çalışıyor. Bırakınca ne oluyor?

7 Eylül 2026 · 23 kaynak

1. 1
   Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group.. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002 · PMID 33567185
2. 2
   Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators.. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216 · PMID 35658024
3. 3
   Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S.. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026;394:e372161 · PMID 42419792
4. 4
   Paccola GP, de Oliveira RF, Mochetti MM, Razera FPM, Vecchi R, Montanher RCP.. Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies. Clin Obes. 2026;16(5):e70111 · PMID 42670242
5. 5
   Pałka W, Moćko P, Śladowska K, Holko P, Kawalec P.. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis. J Endocrinol Invest. 2026 · PMID 42560457
6. 6
   Khodadadiyan A, Khazraei Y, Kamali M, Kolaei K, Aminzadeh P, Yazdanpanah G, Shams A, Feili M, Ghaffari M, Hosseini M, Bazrafshan M, Drissi HB, Arzhangzadeh A.. Long-Term Effects of Orlistat on Lipid Metabolism and Anthropometric Indices: A Meta-Analysis of Clinical Trials. J Obes. 2026;2026:9068305 · PMID 41737647
7. 7
   Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, SELECT Trial Investigators.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232 · PMID 37952131
8. 8
   Eisa N, Barood O.. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026;28(6):4818-4827 · PMID 41877354
9. 9
   Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR, Meira Filho LF, Jones EP, Batchek D, Khandpekar S, Patel R, Awkal B, Pape A, Bahna M, Zamboni M, Prado CM.. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. Ann Intern Med. 2026;179(7):996-1013 · PMID 41996180
10. 10
    Šantić R, Martinović L, Pavlović N, Rušić D, Kumrić M, Martinović D, Tičinović Kurir T, Božić J.. Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. Metabolites. 2026;16(6):364 · PMID 42346344
11. 11
    Deller M, Weiershaus J, Held S, Brinkmann C.. Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat-Free and Skeletal Muscle Mass in Overweight or Obese Individuals-A Systematic Review With Pairwise Meta-Analysis and Network Meta-Analysis of Randomized Controlled Studies. Diabetes Obes Metab. 2026;28(8):6810-6823 · PMID 42144246
12. 12
    Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF, STEP 1 Study Group.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564 · PMID 35441470
13. 13
    Baalmann A, Michel J, Avedissian SN, Pow A, Farris K.. Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. J Manag Care Spec Pharm. 2026;32(6):660-669 · PMID 42166306
14. 14
    Van Laren J, Friesleben C, Gershovich O, Helm L, Patel RJ, Delate T.. Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist. Diabetes Obes Metab. 2026;28(5):3965-3973 · PMID 41713959
15. 15
    Tobaiqy M, Alqutub ST.. Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation. Drug Des Devel Ther. 2026;20:622972 · PMID 42544311
16. 16
    Nauck MA, Punov V, Kang YM, Lim S.. Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. Diabetes Obes Metab. 2026;28(5):4232-4242 · PMID 41757397
17. 17
    Zinzi A, Gaio M, Ruggiero R, Mascolo A, Riemma MA, Cipriani M, Laino LV, Berrino L, Rossi F, Capuano A.. Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Front Pharmacol. 2026;17:1805842 · PMID 42137313
18. 18
    Antonacci G, Bortignon E, Bolognesi M, Piano SS, Cadore A, Camuffo L, Venturini F, Faoro S, Favretto D, Romano A, Mengato D.. Hypoglycaemic coma induced by a falsified semaglutide product: a case report. Eur J Hosp Pharm. 2026;33(5):486-489 · PMID 41125326
19. 19
    Hailu KT, Abriha FN, Duguma YM, Haddad RR, Liyew T, Kasagga A.. Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks. Cureus. 2026;18(6):e110657 · PMID 42437212
20. 20
    Arslan S.. Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation. Clin Nutr ESPEN. 2026;73:103305 · PMID 42036071
21. 21
    de Paulo RS, Bonifácio DB, de Carvalho MHL, Bressan J.. Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. Diabetes Obes Metab. 2026;28(7):5492-5507 · PMID 42037117
22. 22
    Chao AM, Asante R, Sersah ME, Jahangir UA, Peary A, Kudaya D.. A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications. Obes Sci Pract. 2026;12(4):e70162 · PMID 42427356
23. 23
    Bruna-Mejias A, Valenzuela-Fuenzalida JJ, Oyanedel G, Figueroa-Puig J, Cabezas-Salgado JJ, Orellana-Donoso M, Cifuentes-Suazo G, Loro-Ferrer JF.. GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Nutrients. 2026;18(11):1781 · PMID 42280424